Menorrhagia
Assessing and managing women with heavy menstrual bleeding
The definition of heavy menstrual bleeding (HMB) has changed – it is no longer solely defined by millilitres of blood loss per cycle but now includes the impact on a women’s physical, social and emotional quality of life.1
>80%
of women say that HMB affects their relationship with their partner or their performance at work, and it affects attendance at school or work for 68% of sufferers.2
- Munro MG, et al. BJOG 2017;124:185–9 Return to content
- Bitzer J, et al. Open access Journal of Contraception, 2013;4:21–28. Return to content
- Hurskainen R, et al. Acta Obstetricia et Gynecologica 2007;86:749–757. Return to content
Once ‘bothersome bleeding’ has been identified, follow the HELP diagnostic pathway for HMB
Download the interactive HELP treatment algorithm, including clinical considerations for all approved treatment options
Qlaira® Prescribing Information, Mirena® Prescribing Information,
The HELP group is an expert panel of physicians from 12 countries with a special interest in heavy menstrual bleeding (HMB), supported by Bayer.
NICE recommends Mirena® as a first-line pharmaceutical treatment for HMB with no identified pathology.1
- Provides effective relief from idiopathic menorrhagia.2
- Achieves menstrual blood loss reduction of up to 96%.3
- Reduced bleeding promotes the increase of blood haemoglobin levels.2
- Improves quality of life more than usual medical treatments (tranexamic acid, mefenamic acid, combined oestrogen-progestogen or progesterone alone).4
- Totally or occasionally absent menstruation has been associated with prolonged continuation with Mirena®.5
- May effectively manage bleeding problems during the transition through menopause.6
- NICE clinical guidance NG88. Heavy menstrual bleeding: assessment and management, March 2018. Available at: https://www.nice.org.uk/guidance/ng88. Return to content
- Bayer Ltd. Mirena® Summary of Product Characteristics. Return to content
- Stewart A, et al. Br J Obs Gyn 2001;108:74–86. Return to content
- Gupta J, et al. N Engl J Med 2013;368:128–137. Return to content
- Backman T, et al. Br J Obs Gyn 2000;107:335–339. Return to content
- Depypere H and Inki P. Climacteric 2015;18:1–13. Return to content
Heavy Menstrual Bleeding (HMB): evidence-based learning for best practice.
A 30-minute, scientific e-learning course developed by the HELP expert panel of independent physicians*. Three case-based modules cover the diagnostic pathway and treatment algorithm for HMB to help you to counsel your patients effectively.
*The formation of the HELP expert panel and its ongoing work is supported by Bayer AG.
Gain real-world patient insights into heavy menstrual bleeding through this short video that can help both you and your patients relate to the condition.
Recommendations
Reporting adverse events and quality complaints
If you want to report a side effect or quality complaint, please contact your health care professional (e.g. physician or pharmacist) or The Health Products Regulatory Authority, Reports can also be reported directly to Bayer through this link or by emailing directly on adr-reland@bayerhealthcare.com
